Skip to content
    UCB logo

    UCB

    Brussels, BelgiumFounded 2017
    ucbventures.comLinkedIn
    Biotech & Life SciencesHealthcare

    UCB Ventures is an evergreen strategic corporate venture fund established in 2017 by UCB, a global biopharmaceutical company. It makes long-term investments in early-stage companies developing novel therapeutic modalities and platforms, primarily in the US and Europe.

    38% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (42% of deals). Average disclosed round size is $58.4M (across 20 rounds with reported amounts).

    Find people at UCB on Goldilocks AI

    Portfolio

    24

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    0

    Team

    Alicia Irurzun-Lafitte

    Alicia Irurzun-Lafitte

    UCB Ventures Partner

    Steven Biesmans

    Steven Biesmans

    UCB Ventures Principal

    Rahul Khetan

    Rahul Khetan

    Venture Associate

    Robert Fusco

    Robert Fusco

    Associate

    Reiner Class

    Reiner Class

    UCB Ventures Analyst

    Ally Smith

    Ally Smith

    Senior Legal Counsel

    Erica Whittaker

    Erica Whittaker

    Head of UCB Ventures

    Jenny Needham

    Jenny Needham

    Team Coordinator

    MR

    Mohammed Rahmat Pasha

    Managing Director & CEO

    TA

    Tanzim Alamgir

    Managing Director and Chief Executive Officer

    AI

    Alicia Irurzun-Lafitte

    UCB Ventures Partner

    DH

    Delphine Hajaji

    Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    26 investments
    CompanyRoundAmountDate
    SonoThera logoSonoTheraSeries B$125MJan 2026
    SpliceBio logoSpliceBioSeries B$135MJun 2025
    SSplice BioSeries B$135MJun 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    ViaNautis logoViaNautisSeries A$25MNov 2023
    VViaNautis BioSeries A$25MNov 2023
    SSwitch TherapeuticsUnknown$52MJan 2023
    Bingli logoBingliSeries A—Oct 2022
    SpliceBio logoSpliceBioSeries A—Feb 2022
    RRinri TherapeuticsUnknown$13.8MApr 2021
    Stride Bio logoStride BioSeries B$81.5MMar 2021
    EXEVIR BIO logoEXEVIR BIOSeries A—Mar 2021
    SStrideBioSeries B$81.5MMar 2021
    EsoBiotec logoEsoBiotecUnknown$250KJan 2021
    EExeVirSeries A—Jan 2021
    MyHealthTeams logoMyHealthTeamsSeries B$9.4MAug 2019
    Locana logoLocanaSeries A$55MMay 2019
    AAlly TherapeuticsSeed$10MJan 2019
    Ceribell logoCeribellSeries B$35MSep 2018
    SStrideBioSeries A—Jan 2018
    SSyndesi TherapeuticsSeries A—Jan 2018
    Lumos Pharma logoLumos PharmaSeries B$34MApr 2016
    CClementiaDebt$60MJun 2015
    Aetion logoAetionSeries B$11.2M—
    Page 1 of 2

    Top Co-Investors

    New Enterprise Associates7 shared
    Alexandria Venture Investments6 shared
    Ysios Capital5 shared
    Takeda Ventures, Inc.4 shared
    Eli Lilly and Company4 shared
    Roche Venture Fund3 shared
    Sanofi Ventures3 shared
    Northpond Ventures3 shared
    ARCH Venture Partners3 shared
    Asabys Partners3 shared
    Gilde Healthcare3 shared
    4BIO Capital3 shared
    Amgen Ventures2 shared
    Pontifax2 shared
    CaaS Capital2 shared
    Novo Holdings A/S2 shared
    EQT Life Sciences2 shared
    Novartis Pharma AG2 shared
    RA Capital Management2 shared
    BGF2 shared

    Last updated: 20 October 2026